Interferon-alpha can alter the lytic susceptibility of murine bladder transitional cell carcinoma (MBT-2) by their original poor specific cytotoxic tumor infiltrating lymphocytes.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 1732635.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fresh isolated or short term in vitro cultured tumor infiltrating lymphocytes derived from MBT-2 tumor possess little specific cytotoxicity on MBT-2 cells despite the presence of low (10 units/ml.), moderate (500 units/ml.), or high (1000 units/ml.) dose interleukin-2 and irradiated tumor cells; however the lytic susceptibility of the MBT-2 cells and their expression of MHC class I antigen can be significantly enhanced if the tumor cells are preincubated with interferon-alpha for 24 hours. But the specific antitumor activity of tumor infiltrating lymphocytes cannot be further augmented by coculturing them with irradiated interferon-alpha pretreated MBT-2 tumor cells. In vivo experiments by subcutaneous peritumor injection of interferon-alpha (500 units/ml.) combined with interleukin-2 (500 units/ml.) can suppress the tumor growth of those three-day inoculated MBT-2 cells significantly but not on those already established tiny tumors. We therefore concluded that interferon-alpha can alter the specific antitumor activity of tumor infiltrating lymphocytes chiefly through its modulating effect on the target tumor cells instead of the tumor infiltrating lymphocytes.
Medical subject headings
- Carcinoma, Transitional Cell
- Cytotoxicity, Immunologic
- Interferon-alpha
- Lymphocytes, Tumor-Infiltrating
- Urinary Bladder Neoplasms